Scoring system screening for “dual” heart disease

Scoring system improves screening for “dual” heart disease: Aortic stenosis, high-grade narrowing of the aortic valve, and cardiac amyloidosis, in which protein is deposited in the heart muscle, are serious heart diseases, which can be concomitant, especially in older patients. An international study involving a research team led by Julia Mascherbauer and Christian Nitsche from the Division of Cardiology (Department of Medicine II of MedUni Vienna and Vienna General Hospital) has now shown that a scoring system, based on simple clinical parameters, can help to improve diagnosis so as to identify the co-existence of both diseases.

Up until now, it was not clear whether patients with an additional condition, cardiac amyloidosis, would also benefit from a valve replacement. In this heart condition, amyloid protein deposits cause the heart muscle to thicken and harden. As a result, the heart is no longer able to contract and expand evenly, so that the blood supply to the body is compromised.

The recent study looked at the coincidence of both diseases in aortic stenosis patients referred for a TAVR procedure, as well as any prognostic implication. Overall, cardiac amyloidosis was detected in one in eight of the 407 aortic stenosis patients examined. Since it is not economically or logistically feasible to carry out a DPD bone scintigraphy scan (a sensitive test to identify cardiac amyloidosis) on all TAVR patients, the study team developed a scoring system based on simple clinical parameters to screen for dual heart disease.

“The scoring system enables us to use simple clinical parameters such as ECG changes, above-average cardiac hypertrophy or existing or operated carpal tunnel syndrome, to predict the probability of concomitant cardiac amyloidosis in aortic stenosis patients, so that they require further investigation using DPD bone scintigraphy,” says lead investigator Christian Nitsche from the Division of Cardiology, Department of Medicine II of MedUni Vienna and Vienna General Hospital.

The study published in the Journal of the American College of Cardiology also found that both aortic stenosis patients with concomitant cardiac amyloidosis and those without this additional heart disease benefit from TAVR. “The results show that the minimally invasive TAVR technique is suitable for both groups. We therefore conclude that TAVR should not be withheld from aortic stenosis patients who also suffer from cardiac amyloidosis,” says Nitsche.

Further studies are required to determine whether the drugs used to treat cardiac amyloidosis improve survival in dual heart disease on top of aortic valve replacement.

The study was conducted jointly by the Division of Cardiology of MedUni Vienna and Vienna General Hospital and Barts Heart Center in London and presented at the American Heart Association Congress on 13 November 2020.

Service: Journal of the American College of Cardiology

“Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis.” Nitsche C., Thomas A. Treibel et al., J Am Coll Cardiol. Nov 08, 2020. Epublished DOI: 10.1016/j.jacc.2020.11.006. https://www.jacc.org/doi/10.1016/j.jacc.2020.11.006